Deutsche Bank AG Makes New Investment in Palvella Therapeutics, Inc. $PVLA

Deutsche Bank AG acquired a new stake in shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 11,838 shares of the company’s stock, valued at approximately $1,809,000.

Several other large investors have also recently modified their holdings of PVLA. Group One Trading LLC boosted its stake in Palvella Therapeutics by 151.5% during the fourth quarter. Group One Trading LLC now owns 332 shares of the company’s stock worth $35,000 after buying an additional 200 shares during the period. KBC Group NV purchased a new stake in Palvella Therapeutics in the first quarter worth $28,000. Price T Rowe Associates Inc. MD increased its stake in Palvella Therapeutics by 11.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,090 shares of the company’s stock worth $429,000 after purchasing an additional 433 shares during the period. Bank of America Corp DE lifted its position in shares of Palvella Therapeutics by 12.3% during the third quarter. Bank of America Corp DE now owns 4,689 shares of the company’s stock worth $294,000 after purchasing an additional 515 shares during the last quarter. Finally, Russell Investments Group Ltd. purchased a new stake in shares of Palvella Therapeutics during the third quarter valued at $36,000. Institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Trading Down 0.2%

Shares of PVLA stock opened at $149.97 on Friday. Palvella Therapeutics, Inc. has a 12-month low of $49.81 and a 12-month high of $161.38. The business’s fifty day simple moving average is $146.01 and its 200-day simple moving average is $126.90. The company has a market cap of $2.16 billion, a PE ratio of -31.05 and a beta of -0.17.

Palvella Therapeutics (NASDAQ:PVLA) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($1.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.35). On average, equities analysts forecast that Palvella Therapeutics, Inc. will post -6.36 earnings per share for the current year.

Insider Activity

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $152.21, for a total transaction of $654,807.42. Following the transaction, the chief operating officer owned 2,154 shares in the company, valued at approximately $327,860.34. This represents a 66.64% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 17.20% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. Canaccord Genuity Group set a $232.00 price target on shares of Palvella Therapeutics in a research note on Wednesday, August 5th. HC Wainwright restated a “buy” rating and issued a $270.00 target price on shares of Palvella Therapeutics in a research note on Wednesday, July 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Palvella Therapeutics in a research note on Monday, June 29th. Chardan Capital raised Palvella Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 28th. Finally, Stephens reissued an “overweight” rating and issued a $220.00 price objective on shares of Palvella Therapeutics in a research note on Thursday, May 21st. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Palvella Therapeutics has an average rating of “Buy” and a consensus target price of $209.14.

Palvella Therapeutics Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.